Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Key Takeaways Bristol Myers expands Opdivo into new cHL settings, broadening reach across treatment lines.Label expansions and pipeline progress aim to offset generic pressure on legacy drugs like Revlimid.Oncology competition intensifies as Merck and Pfizer advance bispecifics and diversified cancer pipelines.Bristol Myers Squibb (BMY) recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.The FDA approved Opdivo in combination wi ...